{
    "clinical_study": {
        "@rank": "85728", 
        "arm_group": {
            "arm_group_label": "sublingual nicotine\uff0cplacebo", 
            "arm_group_type": "Experimental", 
            "description": "sublingual nicotine\uff1aone or two tablets per hour, up to a maximum of 20 tablets per day Subjects were advised to use the full treatment dose for 4 weeks"
        }, 
        "brief_summary": {
            "textblock": "Nicotine replacement treatment (NRT) can be efficacious for smoking cessation, but used by\n      only a minority of smokers in China. Pharmacogenetic matching may improve treatment outcomes\n      for NRT in subgroups of smokers. The investigators evaluated the efficacy and safety of\n      sublingual nicotine tablets (SNT) for smoking cessation and the association of\n      catechol-O-methyltransferase (COMT) genotype with efficacy in this smoking cessation trial\n      among Chinese smokers."
        }, 
        "brief_title": "Association of Functional COMT Val108/Met Polymorphism With Smoking Cessation in Nicotine Replacement Therapy", 
        "completion_date": {
            "#text": "December 2004", 
            "@type": "Actual"
        }, 
        "condition": "Nicotine Dependence", 
        "condition_browse": {
            "mesh_term": "Tobacco Use Disorder"
        }, 
        "detailed_description": {
            "textblock": "All subjects provided written informed consent after a full explanation of the protocol\n      design."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects motivated to stop smoking and Han Chinese\n\n          -  aged 20-70 years who lived in the Haidian District of Beijing\n\n          -  smoke \u226510 cigarettes/day\n\n          -  have smoked for \u22653 years\n\n          -  carbon monoxide (CO) level \u226510 p.p.m. in exhaled air\n\n        Exclusion Criteria:\n\n          -  a history of \"Diagnostic and Statistical Manual of Mental Disorders\u2014fourth Edition\"\n             (DSM-IV) psychiatric disorder\n\n          -  alcohol abuse and other drug abuse\n\n          -  with pathological changes in the floor of their mouth\n\n          -  cardiovascular disease\n\n          -  taking psychotropic medications\n\n          -  using other forms of tobacco or any other NRT products during the last 6 months\n\n          -  pregnant or breast-feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 13, 2011", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01980550", 
            "org_study_id": "Hongqiang-2010"
        }, 
        "intervention": {
            "arm_group_label": "sublingual nicotine\uff0cplacebo", 
            "description": "The nicotine sublingual tablet is Smokers were recommended to use one or two tablets per hour, up to a maximum of 20 tablets per day. Subjects were advised to use the full treatment dose for 4 weeks. After this time-point, treatment could be tapered off up to the 8-week visit. During the next 4-week follow-up phase, no further medication was dispensed. Staff, who dispensed medications, were not involved in treating the subjects. During each patient visit, the importance of adequate dosing with study medication was emphasized. The medication was free of charge. In addition, all participants received six sessions of standardized behavioral group counseling focusing on self-monitoring and behavioral modification approaches.", 
            "intervention_name": "sublingual nicotine", 
            "intervention_type": "Drug", 
            "other_name": "nicotine sublingual tablet"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Nicotine", 
                "Nicotine polacrilex"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 10, 2013", 
        "number_of_arms": "1", 
        "official_title": "Association of Functional COMT Val108/Met Polymorphism With Smoking Cessation in Nicotine Replacement Therapy", 
        "overall_official": {
            "affiliation": "VA Medical Center\uff0cUSA", 
            "last_name": "xiang y zhang, professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2004", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Changes in the exhaled carbon monoxide (CO) level during the 12-week study", 
            "safety_issue": "Yes", 
            "time_frame": "The first was 1 day before quit day (baseline), followed by visits after 1, 2, 4, 6 and 8 weeks at the end of treatment (EOT), with a final follow-up visit at 12 weeks."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01980550"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute on Drug Dependence, China", 
        "sponsors": {
            "collaborator": {
                "agency": "Bronx VA Medical Center", 
                "agency_class": "U.S. Fed"
            }, 
            "lead_sponsor": {
                "agency": "National Institute on Drug Dependence, China", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2004", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}